Skuteczność stosowania niezmydlających się frakcji awokado i oleju sojowego w chorobie zwyrodnieniowej stawów Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2021
Słowa kluczowe:
choroba zwyrodnieniowa stawów kolanowych, leczenie farmakologiczne, niezmydlające się frakcje awokado i oleju sojowego
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroba zwyrodnieniowa stawów, dotykająca ok. 18% kobiet i 10% mężczyzn po 60. r.ż., stanowi bez wątpienia poważny problem społeczny. Podstawowe zmiany patologiczne w przebiegu choroby zwyrodnieniowej dotyczą degeneracji i utraty chrząstki stawowej oraz powstawania wtórnych zmian wytwórczych w nasadach kostnych. Dolegliwości bólowe towarzyszące zmianom degeneracyjnym znacznie obniżają jakość życia chorych. Celem artykułu jest omówienie możliwości zastosowania niezmydlających się frakcji awokado i oleju sojowego w celu opanowania objawów choroby zwyrodnieniowej stawów kolanowych na podstawie opisu przypadku pacjenta.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Walewska, E. (2021). Skuteczność stosowania niezmydlających się frakcji awokado i oleju sojowego w chorobie zwyrodnieniowej stawów. Medycyna Faktów , 14(2(51), 188-192. https://doi.org/10.24292/01.MF.0221.8
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zhang W, Doherty M, Peat G et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69(3): 483-9.
2. Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018; 26(3): 319-25.
3. Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12): 1145-55.
4. Salehi B, Rescigno A, Dettori T et al. Avocado-soybean unsaponifiables: a panoply of potentialities to be exploited. Biomolecules. 2020; 10(1): 130.
5. Henrotin YE, Sanchez CH, Deberg MA et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol. 2003; 30(8): 1825-34.
6. Altinel L, Saritas ZK, Kose KC et al. Treatment with unsaponifiable extracts of avocado and soybean increases TGF-β1 and TGF-β2 levels in canine joint fluid. Tohoku J Exp Med. 2007; 211(2): 181-6.
7. Gabay O, Gosset M, Levy A et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis Cartilage. 2008; 16(3): 373-84.
8. Ownby SL, Fortuno LV, Au AY et al. Expression of pro-inflammatory mediators is inhibited by an avocado/soybean unsaponifiables and epigallocatechin gallate combination. J Inflamm. 2014; 11(1): 1-7.
9. Kut‐Lasserre C, Miller CCh, Ejeil AL et al. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP‐2), stromelysin 1 (MMP‐3), and tissue inhibitors of matrix metalloproteinase (TIMP‐1 and TIMP‐2) secretion by human fibroblasts in culture. J Periodontol. 2001; 72(12): 1685-94.
10. Angermann P. Avocado/soybean unsaponifiables in the treatment of knee and hip osteoarthritis. Ugeskr Laeger. 2005; 167(33): 3023-5.
11. Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997; 64(12): 825-34.
12. Appelboom T, Schuermans J, Verbruggen G et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand J Rheumatol. 2001; 30(4): 242-7.
13. Maheu E, Cadet Ch, Marty M et al. Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014. 73(2): 376-84.
14. Darestani RT, Bakhshi H, Sahraee R. Comparing the efficacy and safety of Diclofenac and Piascledine in patients with knee osteoarthritis. Pajoohandeh Journal. 2013; 17(6): 272-8.
15. Pavelka K, Coste P, Géher P et al. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010; 29(6): 659-70.
16. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016; 54(5): 217.
2. Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018; 26(3): 319-25.
3. Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12): 1145-55.
4. Salehi B, Rescigno A, Dettori T et al. Avocado-soybean unsaponifiables: a panoply of potentialities to be exploited. Biomolecules. 2020; 10(1): 130.
5. Henrotin YE, Sanchez CH, Deberg MA et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol. 2003; 30(8): 1825-34.
6. Altinel L, Saritas ZK, Kose KC et al. Treatment with unsaponifiable extracts of avocado and soybean increases TGF-β1 and TGF-β2 levels in canine joint fluid. Tohoku J Exp Med. 2007; 211(2): 181-6.
7. Gabay O, Gosset M, Levy A et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis Cartilage. 2008; 16(3): 373-84.
8. Ownby SL, Fortuno LV, Au AY et al. Expression of pro-inflammatory mediators is inhibited by an avocado/soybean unsaponifiables and epigallocatechin gallate combination. J Inflamm. 2014; 11(1): 1-7.
9. Kut‐Lasserre C, Miller CCh, Ejeil AL et al. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP‐2), stromelysin 1 (MMP‐3), and tissue inhibitors of matrix metalloproteinase (TIMP‐1 and TIMP‐2) secretion by human fibroblasts in culture. J Periodontol. 2001; 72(12): 1685-94.
10. Angermann P. Avocado/soybean unsaponifiables in the treatment of knee and hip osteoarthritis. Ugeskr Laeger. 2005; 167(33): 3023-5.
11. Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997; 64(12): 825-34.
12. Appelboom T, Schuermans J, Verbruggen G et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand J Rheumatol. 2001; 30(4): 242-7.
13. Maheu E, Cadet Ch, Marty M et al. Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014. 73(2): 376-84.
14. Darestani RT, Bakhshi H, Sahraee R. Comparing the efficacy and safety of Diclofenac and Piascledine in patients with knee osteoarthritis. Pajoohandeh Journal. 2013; 17(6): 272-8.
15. Pavelka K, Coste P, Géher P et al. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010; 29(6): 659-70.
16. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016; 54(5): 217.